Myosin II Inhibition in Smooth Muscle Physiology

Myosin II, a hexameric motor protein, underpins force generation in smooth muscle cells by converting chemical energy from ATP hydrolysis into mechanical work. Its cycle of cross-bridge attachment, power stroke and detachment governs vascular tone, gastrointestinal motility and airway calibre. Targeted inhibition of myosin II offers a means to modulate smooth muscle contractility in conditions such as hypertension, asthma and bladder outlet obstruction. Pharmacological agents—most notably blebbistatin and its derivatives—stabilise specific ATPase intermediates, preventing phosphate release and actin binding. Advances in inhibitor design have focused on solubility, photostability and isoform selectivity to enhance efficacy and reduce off-target effects. Mechanistic studies reveal the importance of allosteric binding sites and upstream regulators such as Rho-associated kinase. Translational research is exploring myosin II inhibition as a novel therapeutic strategy to attenuate aberrant smooth muscle contraction without affecting cardiac or skeletal muscle functions.

Research from Nature Portfolio

Recent studies have introduced a para-amino substituted blebbistatin derivative featuring markedly enhanced aqueous solubility and photochemical stability while retaining potent myosin II inhibition. This compound overcomes aggregation and phototoxicity issues of earlier inhibitors, broadening applications that require high concentrations or light exposure. In parallel, investigations into the diffusion dynamics of non-muscle myosin II under direct allosteric inhibition versus upstream kinase blockade have uncovered that inhibitor effects vary with mechanical load and filament organisation. These findings highlight that allosteric inhibitors can differentially modulate myosin mobility and contractile behaviour in distinct subcellular contexts, suggesting load-dependent pharmacology may be a critical consideration for smooth muscle targets.

Myosin II Inhibition in Smooth Muscle Physiology publication trend

The graph below shows the total number of articles in myosin ii inhibition in smooth muscle physiology across all publications each year (not limited to Nature Index journals).

Technical terms

Myosin II: A motor protein complex responsible for smooth muscle contraction via ATP-driven interactions with actin.

Actomyosin ATPase: The enzymatic activity of the myosin head that hydrolyses ATP to generate force.

Blebbistatin: A small-molecule inhibitor that stabilises myosin II in a low-affinity state with bound ADP and phosphate.

Allosteric inhibition: Regulation of protein function through binding at a site distinct from the active site.

Isoform specificity: Selective action of an inhibitor on distinct myosin heavy or light chain variants.

References

1. A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative. Scientific Reports (2016).
2. Mechanism of Blebbistatin Inhibition of Myosin II*. Journal of Biological Chemistry (2004).
3. Effect of allosteric inhibition of non-muscle myosin 2 on its intracellular diffusion. Scientific Reports (2020).
4. Blebbistain, a Myosin II Inhibitor, as a Novel Strategy to Regulate Detrusor Contractility in a Rat Model of Partial Bladder Outlet Obstruction. PLOS ONE (2011).
5. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2. Journal of Pharmacology and Experimental Therapeutics (2021).